Intravesical Chemotherapy Treatment of Superficial Bladder Cancer

• Status: Completed
• Trial end date: 2004-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase II study where chemotherapy (gemcitabine) is given into the urinary bladder.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

• Superficial bladder cancer

• No prior chemotherapy

Exclusion Criteria:

• Grade 3 tumors

• Papillary tumors invading connective tissue

• Significant urologic disease, possible interfering with intravesical therapy